Stockscreener 앱 받기
7.13
4.30%
-0.32
시간 외 거래:
7.10
-0.03
-0.42%
Organon Co 주식(OGN)의 최신 뉴스
Co. (7XP) stock profit from AI boomChart Signals & Consistent Profit Alerts - newser.com
Discipline and Rules-Based Execution in OGN Response - news.stocktradersdaily.com
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
Henlius, Organon win US FDA approval of first Perjeta biosimilar - BioWorld MedTech
Co. (7XP) stock profit from automation waveWeekly Trade Recap & Fast Gain Swing Alerts - newser.com
Organon Executive Chairman of the Board Acquires 525% More Stock - simplywall.st
Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - Yahoo Finance
Global Contraceptive Devices Market is Set to Accelerate at a CAGR of ~6% by 2032, as Demand for Advanced Birth Control Solutions Rises | DelveInsight - GlobeNewswire Inc.
Organon, Shanghai Henlius Biotech Says FDA Clears Poherdy as Pertuzumab Biosimilar - MarketScreener
The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call - The Globe and Mail
Henlius, Organon (NYSE: OGN) Win FDA Approval for POHERDY, First Pertuzumab Biosimilar - Stock Titan
The 5 Most Interesting Analyst Questions From Organon's Q3 Earnings Call - Finviz
Organon Q3 2025 Earnings: Revenue & EPS Beat EstimatesNews and Statistics - IndexBox
Organon (OGN) Price Target Decreased by 10.77% to 9.86 - Nasdaq
Are Margin Pressures Reshaping Organon’s (OGN) Long-Term Competitive Position? - simplywall.st
Organon & Co. (OGN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - Business Wire
Earnings Release: Here's Why Analysts Cut Their Organon & Co. (NYSE:OGN) Price Target To US$9.67 - simplywall.st
Executive Chairman of the Board of Organon Carrie Cox Buys 525% More Shares - Yahoo Finance
First Perjeta Biosimilar Is Approved In The US For Henlius And Organon - Citeline News & Insights
Executive Chair Makes Bold Move with Major Organon Stock Purchase - TipRanks
Organon Shares Face Mounting Pressure Amid Strategic Shifts - AD HOC NEWS
Laborie to acquire Organon’s JADA System for $465M - NJBIZ
Bank of America Securities Sticks to Its Sell Rating for Organon (OGN) - The Globe and Mail
Organon (OGN): Assessing Valuation After Recent Share Price Rebound - Yahoo Finance
Organon (OGN) Stock Trades Down, Here Is Why - The Globe and Mail
Is Organon’s 15% Share Price Jump a Sign of Real Value in 2025? - Yahoo Finance
Organon & Co. Earnings Call: Mixed Results Amid Challenges - TipRanks
JP Morgan Lowers Price Target for Organon (OGN) to $12.00 | OGN Stock News - GuruFocus
Organon & Co. (OGN) Climbs 13.7% Ahead of Dividends - Insider Monkey
Organon: Q3 Earnings Lift Struggling StockBut Not For Long, I Suspect (NYSE:OGN) - Seeking Alpha
Organon Co earnings beat by $0.07, revenue topped estimates - Investing.com Philippines
Organon Analysts Cut Their Forecasts Following Q3 Results - Benzinga
Organon lowers 2025 revenue guidance to $6.2B–$6.25B amid U.S. Nexplanon headwinds and Jada divestiture - MSN
Organon & Co. (NYSE:OGN) Q3 2025 Earnings Call Transcript - MSN
Organon (OGN) Analyst Rating Update: Morgan Stanley Lowers Price Target | OGN Stock News - GuruFocus
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Cuts Target Price to $9 - 富途牛牛
Organon price target lowered to $9 from $10 at Morgan Stanley - TipRanks
Organon & Co (OGN) Q3 2025 Earnings Call Highlights: Strong Biosimilars Performance Amidst ... By GuruFocus - Investing.com Canada
Earnings call transcript: Organon Q3 2025 beats forecasts, stock surges By Investing.com - Investing.com Philippines
Organon to divest its JADA® System for USD 465M to Laborie - Medical Buyer
Organon Reports Results for the Third Quarter Ended September 30, 2025 - BioSpace
OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration - Yahoo Finance
Decoding Organon & Co (OGN): A Strategic SWOT Insight - GuruFocus
Organon & Co. Reports Modest Q3 Revenue Growth - TipRanks
Organon (OGN) Q3 Earnings and Revenues Beat Estimates - sharewise.com
Organon: Q3 Earnings Snapshot - Chron
[Form 4] Organon & Co. Insider Trading Activity - Stock Titan
Officer Arjona Ferreira Acquires 4,139 Of Organon & Co [OGN] - TradingView
Organon to sell Jada postpartum haemorrhage device - FemTech World
Organon & Co.: Is It Time to Buy or Watch? - StocksToTrade
Organon (OGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
1.33%
자본화:
|
볼륨(24시간):